share_log

SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $130

Benzinga Real-time News ·  Feb 3, 2023 06:14

SVB Leerink analyst Joseph Schwartz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $122 to $130.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment